Patient-derived organoids as a preclinical platform for precision medicine in colorectal cancer.

ABSTRACT: Patient-derived organoids are being considered as models that can help guide personalized therapy through in vitro anticancer drug response evaluation. However, attempts to quantify in vitro drug responses in organoids and compare them with responses in matched patients remain inadequate. In this study, we investigated whether drug responses of organoids correlate with clinical responses of matched patients and disease progression of patients. Organoids were established from 54 patients with colorectal cancer who (except for one patient) did not receive any form of therapy before, and tumor organoids were assessed through whole-exome sequencing. For comparisons of in vitro drug responses in matched patients, we developed an 'organoid score' based on the variable anticancer treatment respon

SUBMITTER: Cho YW 

PROVIDER: S-EPMC9208081 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature